Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
110.10
+2.85 (2.66%)
At close: Oct 31, 2025, 4:00 PM EDT
107.90
-2.20 (-2.00%)
After-hours: Oct 31, 2025, 7:54 PM EDT
Spruce Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts that cover Spruce Biosciences stock have a consensus rating of "Hold" and an average price target of $150.5, which forecasts a 36.69% increase in the stock price over the next year. The lowest target is $37.5 and the highest is $254.
Price Target: $150.5 (+36.69%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Spruce Biosciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold → Buy Upgrades $254 | Hold → Buy | Upgrades | $254 | +130.70% | Oct 28, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $10 → $160 | Hold | Maintains | $10 → $160 | +45.32% | Oct 21, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $113 → $38 | Hold | Maintains | $113 → $38 | -65.94% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 16, 2024 |
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 12, 2024 |
Financial Forecast
Revenue This Year
1.02M
from 4.91M
Decreased by -79.23%
Revenue Next Year
n/a
from 1.02M
EPS This Year
-65.03
from -96.39
EPS Next Year
-11.54
from -65.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.1M | n/a | |
| Avg | 1.0M | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -57.2% | - | |
| Avg | -79.2% | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -53.55 | -11.88 | |
| Avg | -65.03 | -11.54 | |
| Low | -74.97 | -11.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.